A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

BACKGROUND: To evaluate the impact of treatment on health states that affect patients’ quality of life in advanced follicular lymphoma. METHODS: A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marc...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcus, R, Aultman, R, Jost, F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813752/
https://www.ncbi.nlm.nih.gov/pubmed/19920818
http://dx.doi.org/10.1038/sj.bjc.6605443
Descripción
Sumario:BACKGROUND: To evaluate the impact of treatment on health states that affect patients’ quality of life in advanced follicular lymphoma. METHODS: A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marcus et al, 2008). RESULTS: Cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with cyclophosphamide, vincristine, and prednisone (CVP)-treated patients. CONCLUSION: Rituximab plus CVP-treated patients reached a significant and clinically meaningful improvement within 12 months in quality-adjusted survival compared with CVP.

Ejemplares similares